BBOTNasdaq

BridgeBio Oncology Therapeutics, Inc.

Alert me on BBOT

Insider buys, 6 months

Congress trades, 6 months

Signals, 6 months

Six months

After each filing

No purchase or sale on this ticker by a member of Congress or an insider yet.

Filings for BBOT

35 held · newest 535 held · newest 2

Loading the filings.

See all 35 filings for BBOT

Aeon news and offers by email

New sources, new features and offers like our founding price. A few times a month at most. Stop any time.

Signal history

No signal for this ticker yet. A signal is written when insider buying here scores one dot or more.

Stakes

Jul 1, 2026 Schedule 13D, amended

Bihua Chen: 22.3%, 17,878,594 shares

Sep 30, 2025 Schedule 13G, amended

Citadel Advisors LLC: 3.2%, 2,528,762 shares

Sep 30, 2025 Schedule 13G, amended

Adage Capital Management, L.P.: 1.9%, 1,487,621 shares

Sep 4, 2025 Schedule 13G

BC Global Opportunities IX LP: 5.5%, 4,365,747 shares

Schedule 13D is filed within 5 business days of crossing 5 percent by an investor who may seek to influence the company. Schedule 13G is filed by a passive holder, and a large institution has up to 45 days after the quarter end.

Government contracts, last 12 months

Awards of $10M and up, from USAspending · context, not a signal

No contracts of $10M or more in the last 12 months.

Lobbying

Last four quarters

No lobbying reports on file.